Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cyclerion Therapeutics stock

Own Cyclerion Therapeutics stock in just a few minutes.

Cyclerion Therapeutics, Inc is a biotechnology business based in the US. Cyclerion Therapeutics shares (CYCN) are listed on the NASDAQ and all prices are listed in US Dollars. Cyclerion Therapeutics employs 34 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Cyclerion Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CYCN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cyclerion Therapeutics share price

Use our graph to track the performance of CYCN stocks over time.

Cyclerion Therapeutics shares at a glance

Information last updated 2021-04-29.
52-week range$2.18 - $8.96
50-day moving average $3.20
200-day moving average $3.32
Wall St. target price$4.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.74

Buy Cyclerion Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cyclerion Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cyclerion Therapeutics financials

Revenue TTM $2.3 million
Gross profit TTM $2.3 million
Return on assets TTM -32.52%
Return on equity TTM -98.97%
Profit margin 0%
Book value $1.75
Market capitalisation $78 million

TTM: trailing 12 months

Shorting Cyclerion Therapeutics shares

There are currently 717,858 Cyclerion Therapeutics shares held short by investors – that's known as Cyclerion Therapeutics's "short interest". This figure is 6.7% down from 769,315 last month.

There are a few different ways that this level of interest in shorting Cyclerion Therapeutics shares can be evaluated.

Cyclerion Therapeutics's "short interest ratio" (SIR)

Cyclerion Therapeutics's "short interest ratio" (SIR) is the quantity of Cyclerion Therapeutics shares currently shorted divided by the average quantity of Cyclerion Therapeutics shares traded daily (recently around 321909.41704036). Cyclerion Therapeutics's SIR currently stands at 2.23. In other words for every 100,000 Cyclerion Therapeutics shares traded daily on the market, roughly 2230 shares are currently held short.

However Cyclerion Therapeutics's short interest can also be evaluated against the total number of Cyclerion Therapeutics shares, or, against the total number of tradable Cyclerion Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cyclerion Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Cyclerion Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0231% of the tradable shares (for every 100,000 tradable Cyclerion Therapeutics shares, roughly 23 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cyclerion Therapeutics.

Find out more about how you can short Cyclerion Therapeutics stock.

Cyclerion Therapeutics share dividends

We're not expecting Cyclerion Therapeutics to pay a dividend over the next 12 months.

Cyclerion Therapeutics share price volatility

Over the last 12 months, Cyclerion Therapeutics's shares have ranged in value from as little as $2.18 up to $8.96. A popular way to gauge a stock's volatility is its "beta".

CYCN.US volatility(beta: 2.06)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyclerion Therapeutics's is 2.0626. This would suggest that Cyclerion Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Cyclerion Therapeutics overview

Cyclerion Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site